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Abstract Psoriatic arthritis (PsA) is an inflammatory arthrop-
athy associated with skin and/or nail psoriasis. TNF-α is an
essential cytokine for the host defense, and its depletion by
treatment may facilitate the risk of infections or their reacti-
vation. The aim of this study was to evaluate the efficacy and
safety of TNF-α blockers in patients with PsA and concom-
itant latent tuberculosis infection (LTBI) comparing their out-
come with non-infected PsA patients. This is a retrospective
study in 321 patients with PsA, attending the Psoriatic
Arthritis Clinic at the University Federico II of Naples, who
had an inadequate response to DMARDs and started therapy
with TNF-α blockers. We identified 40 patients with LTBI,
who were included in this study along with 40 not infected
PsA patients as control group. At baseline (T0) and every
3 months for 2 years (T2), data concerning PsA activity were
registered. All patients underwent chest X-ray every 6 months
(or 12 if appropriate). In each group, 22 patients were on
etanercept therapy, 14 on adalimumab, and 4 on infliximab.
Anti-TNF-α therapy was effective in both group of patients,
and no statistically significant differences were found in the
analysis of the study variables between the two groups from
T0 to T2. No serious adverse events occurred in both groups,
and no patient was withdrawn from therapy. Our experience
suggests that anti-TNF-α treatment is effective and safe in
PsA patients with concomitant LTBI. Therefore, neither LTBI
nor chemoprophylaxis seems to influence the course of anti-
TNF-α therapy.
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Introduction
Psoriatic arthritis (PsA) is an inflammatory arthropathy, asso-
ciated with skin and/or nail psoriasis [1–3] and other possible
systemic features [4–6].
In the last decade, the introduction of biologic drugs, in
particular tumor necrosis factors (TNF)-α blockers, has
opened new horizons for patients and rheumatologists in the
treatment of PsA and other rheumatic diseases [7–10].
The use of these agents has outlined the importance of
evaluating their safety, as it may expose patients to an in-
creased risk of developing infections, in particular tuberculo-
sis (TB) [11].
The global prevalence of TB is still close to 9 million,
mainly in underdeveloped countries. This condition is be-
lieved to affect one third of the world’s population, with a
natural history showing a progression to active disease in only
5 % of cases [12].
TNF-α is an essential pro-inflammatory cytokine also in-
volved in the host defense againstMycobacterium tuberculosis
(MTB) [13, 14]. Therefore, patients eligible for anti-TNF-α
therapy require careful evaluation and need to be investigated
about possible previous exposure to MTB, as its use may
expose patients to an increased risk of developing active TB
and reactivation of latent tuberculosis infection (LTBI) [15].
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The use of TNF-α blockers in psoriatic arthritis patients
with latent tuberculosis infection
The aim of this study was to evaluate the efficacy and
safety of TNF-α blockers in patients with PsA and concom-
itant LTBI comparing their outcome with non-infected PsA
patients.
Patients and methods
We performed a retrospective study, from January 2005 to
December 2011, in 321 Caucasian patients with PsA, with no
specific exposure risk to TB, attending the Psoriatic Arthritis
Clinic at the University Federico II of Naples, who had an
inadequate response to disease-modifying antirheumatic
drugs (DMARDs) and started therapy with TNF-α blockers.
Before starting anti-TNF-α therapy, all patients, according
to our screening protocol [15], undergo clinical medical his-
tory, physical examination, laboratory standard tests, chest X-
ray, and tuberculin skin test (TST). Patients, not vaccinated,
with a positive TST are considered affected by LTBI.
Therefore, they are not immediately eligible for TNF-α
blocker therapy and have to start treatment for LTBI before
starting biologic therapy. Negative TST patients, if not treated
with immunosuppressive drugs or steroids and if immuno-
competent, started TNF-α blocker therapy at time of enroll-
ment, performing an INF-γ release assay (IGRA) every
12 months.
In case of negative patients under immunosuppressive
drugs or prolonged steroid therapy or positive patients previ-
ously vaccinated, we perform in addition an IGRA test.
Treatment for LTBI consists of a 9-month therapy with
isoniazid monitoring adverse events, in particular liver func-
tion tests, monthly. Anti-TNF-α treatment was always started
after the first 45 days of antitubercular therapy.
We identified 40 patients with LTBI, who were included in
this study along with 40 not infected PsA patients as control
group, matched for age, sex, and disease duration. For all
patients included in the study, we collected the following data
at starting anti-TNF-α therapy (T0) and every 3months for the
2 years (T2) of follow up: physical examination, recording of
vital signs, tender joint count (TJC; 68 tender joints), swollen
joint count (SJC; 66 swollen joints), Health Assessment
Questionnaire (HAQ), Psoriasis Area and Severity Index
(PASI), visual analogic scale (VAS), erythrocyte sedimenta-
tion rate (ESR), and C-reactive protein (CRP). All patients
underwent chest X-ray every 6 months (or 12 if appropriate).
Tuberculin skin test
Two units (0.1 ml) of standard preparation of PPD RT-23
(Statens Serum Institut, Copenhagen, Denmark) were injected
in the intradermal region of the forearm volar surface
(Mantoux method). The reaction was read at 72 h with the
transverse diameter in millimeters of induration.
The cutoff for a positive skin test was defined as an indu-
ration area greater than or equal to 5 mm in diameter.
QuantiFERON-TB Gold In-Tube
QuantiFERON-TB Gold In-Tube (QFT-GIT) test used de-
signed (1 mL) blood collection tubes that were coated with
M. tuberculosis-specific antigens [ESAT-6, CFP-10, and TB
7.7(p4)], along with a negative and a positive control tube. An
enzyme-linked immunosorbent assay (ELISA) was used to
measure the amount of IFN-γ present in each of the three
tubes (Nil control, TB-Antigen, Mitogen control).
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS
Inc., Chicago, IL, USA). Descriptive statistics included mean
values and standard deviation (SD) of the continuous vari-
ables and percentages and proportions of the categorical var-
iables. For the variables of interest, a difference (delta) be-
tween T2 and T0 was computed, and Student’s test (for paired
samples) was used for the analysis.
To compare continuous variables and dichotomous
ones, Mann-Whitney and χ2 tests were performed,
respectively.
Correlations between study variables have been calculated
using analysis of covariance (ANCOVA) and logistic regres-
sion. For logistic regression, different methods were used for
the selection of variables (full model, backward, stepwise) to
exclude the influence of the different methodologies. To check
the effects of possible confounding variables, which can affect
TST results, we computed the correlation coefficients,
checking the specific effects of the different variables, as
described successively.
In the ANCOVA, we compared values and changes (at T0
and T2) in CRP, ESR, VAS, TJC, SJC, HAQ, and PASI
between the two groups, adjusting for the following variables:
type and duration of therapy with anti-TNF; type, number, and
duration of concomitant DMARD; use and duration of con-
comitant steroids; and use and duration of isoniazid.
Results
On the basis of our screening, 40 patients (12.5 %) (group 1)
were diagnosed to have LTBI (12 males and 28 females, mean
age 51.6±12 years). All patients had a negative history of
contacts and chest X-ray negative for TB. Among 281 not
infected patients, we selected 40 consecutive patients (group
2) (12 males and 28 females, mean age 51.4±11.9 years), who
used the TNF-α blockers for the entire 2-year period of
observation, matched for gender, age, disease duration, and
type of TNF-α blocker.
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Demographic and clinical characteristics at baseline of both
groups selected for this study were reported in Table 1.
At recruitment, patients of group 1 had used steroids for a
mean period of time greater than patients of group 2 (10.8±6.4
vs 6.3±4.8 months; p=0.32). In detail, steroid therapy had
been used in 26 patients of group 1 and 24 of group 2.
Moreover, the mean duration of DMARDs treatment was
greater in group 2 vs group 1 (41.7±40.8 vs 24.5±
38.6 months; p=0.21). In group 1, a total of 11 (28%) patients
was taking immunosuppressive therapy (cyclosporine n=1,
methotrexate n=7, leflunomide n=1, salazopyrin n=2). In
group 2, a total of 15 (38 %) patients was taking immunosup-
pressive therapy (cyclosporine n=1, methotrexate n=11,
leflunomide n=1, salazopyrin n=2).
No statistically significant differences were found in the
comparison between the two groups.
There was no significant correlation between the TST
result and previous therapies with steroids and DMARDs
(odds ratio 1.73, IC 0.53–6.57).
Effectiveness and safety of anti-TNF-α
Patients of group 1 started anti-TNF-α therapy after at least
45 days on prophylactic therapy with isoniazid. Patients of
group 2, who started anti-TNF-α therapy, performed IGRA
test every 12 months to detect a possible LTBI occurrence.
In each group, 22 patients were on etanercept therapy, 14
on adalimumab, and 4 on infliximab.
Anti-TNF-α therapy was effective in both groups of pa-
tients, and no statistically significant differences were found in
the analysis of the study variables between the two groups
from T0 to T2 (Table 2).
No serious adverse events occurred in both groups, and no
patient was withdrawn from therapy. During the follow-up
period, all patients on steroid reduced gradually and
discontinued steroid within the first 3 months, while
DMARDs therapy was continued for the entire 2-year period.
Among patients of group 1, no one developed active TB
during follow-up, while two patients of group 2 showed
positive IGRA results after 1 year of treatment. In those cases,
biologic therapy was temporally stopped and isoniazid thera-
py was started. After 45 days, no signs of active MTB infec-
tion occurred and biologic therapy was restarted.
Discussion
This paper reports our experience in PsA patients with con-
comitant LTBI under anti-TNF-α drugs. This topic is still
substantially underestimate in the literature. However, given
the epidemiological dynamics, it may represent an emerging
question which we need to face.
The results of this study show that the presence of concom-
itant LTBI in PsA patients does not influence the effectiveness
of anti-TNF-α therapy during the follow-up period. In fact,
TNF-α blockers, as expected, improved signs of articular and
cutaneous involvement and ameliorated function and quality
of life in patients of both groups after 24 months of therapy.
Further important result concerns safety: there were no
cases of active tuberculosis in both groups during the
follow-up period.
Although anti-TNF-α agents are effective in the treatment
of PsA, their use has been recognized as a risk factor for
active tuberculosis development in patients with immune-
mediated inflammatory diseases, including rheumatoid ar-
thritis (RA), ankylosing spondylitis (AS), Crohn’s disease,
PsA, and psoriasis [16, 17]. The mechanism by which
TNF-α antagonists reactivate latent TB is not fully under-
stood. In fact, TNF-α is an essential cytokine for the host’s
defense against infective pathogens [14]. It has shown that
Table 1 Demographic and clinical characteristic of two groups of pa-
tients at baseline
Group 1 Group 2
Number 40 40
Female, n 28 28
Age (years) 51.6±12 51.4±11.9
Disease duration (months) 58.44±35.28 59.4±33.6
CRP (mg/dl) 0.9±1.2 0.4±0.2






Data expressed as mean±standard deviation, unless otherwise indicated
CRP C-reactive protein, ESR erythrocyte sedimentation rate, VAS visual
analogic scale, HAQ Health Assessment Questionnaire, TJC tender joint
count, SJC swollen joint count, PASI Psoriasis Area and Severity Index
Table 2 Comparison of variation of clinical characteristic in both groups
of patients at T0 and T2
Group 1 Group 2 P
CRP (mg/dl) 0.306 0.081 0.6085
ESR (mm/hr) 0.362 0.034 0.9609
VAS 0.0001 0.0001 0.2509
HAQ 0.0001 0.0001 0.2593
TJC 0.0001 0.0001 0.1772
SJC 0.017 0.0001 0.8446
PASI 0.0001 0.0001 0.3531
CRP C-reactive protein, ESR erythrocyte sedimentation rate, VAS visual
analogic scale, HAQ Health Assessment Questionnaire, TJC tender joint
count, SJC swollen joint count, PASI Psoriasis Area and Severity Index
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during MTB infection, TNF-α is produced transiently and
focally by granulomas in response to mycobacterial chal-
lenge [13]. It contributes to their containment and elimina-
tion, suggesting a pivotal role of TNF-α in defense mecha-
nisms against microorganisms [13].
In animal models, TNF-α plays a central role in mediating
mycobacterial infections, and soluble TNF (especially
membrane-bound TNF) expressed by activated macrophages
and T lymphocytes is essential in protecting against TB infec-
tion [18].
It has been observed that most cases of TB develop soon
after treatment starting and correspond to reactivation of LTBI
[19, 20]. Several recommendations for screening patients with
LTBI infection and for the treatment of such patients before
initiating anti-TNF-α have been proposed, even if at the
present there are no international guidelines for monitoring
of LTBI during biologic treatment and the data are poor [15].
According to these recommendations, several studies have
shown that isoniazid therapy for 6 and 12 months in patients
with LTBI is more effective than placebo in preventing reac-
tivation, and the best benefit can be obtained with 9 months of
therapy [21]. In our population, none of the patients treated
with isoniazid developed serious toxicity in the liver, but it
remains a threat that should be considered, especially in the
event of concomitant use of hepatotoxic drugs other than
isoniazid or methotrexate [22, 23]. Effectiveness of chemo-
prophylaxis is limited not only by the efficacy of the drug but
also by patient adherence to therapy.
A recent open-label study tested the efficacy and the toler-
ability of a 3-month regimen with isoniazid plus rifampicin,
showing that this therapy could be useful in patients with
rheumatic conditions proposed for anti-TNF therapy [24].
The French Research Axed on Tolerance of Biotherapies
(RATIO) registry records the annual incidence rate of TB in
patients treated with anti-TNF-α blockers, adjusted for age
and sex, with the French population used as reference [25].
Data from this registry report 69 cases of active TB in patients
with anti-TNF-α for a period of 3 years for a total of 57,711
patient-years [25]. TB cases were related to infliximab and
adalimumab therapy, and the authors underline that none of
the patients had received correct LTBI chemoprophylaxis
according to the French recommendations [25].
The British registry confirms these data, underlining a
relative risk of TB three to four times higher for the monoclo-
nal antibodies than for etanercept. In addition, the data show a
greater increased risk of extrapulmonary disease with the
monoclonal antibodies [26].
In our study we did not observe any case of reactivation of
TB in patients with LTBI treated with TNF-α blockers. This
result may be affected by the relative small sample size. On
the other hand, it should be considered screening, chemopro-
phylaxis, and monitoring of patients [15], which may explain
this optimal result. In fact, the question of compliance to
therapy seems to be critical. Current evidence indicates that
prophylaxis may be ineffective in up to 30 % of cases, when
patient adherence to therapy is uncertain [22].
Recently, we have suggested that screening and constant
monitoring of LTBI during TNF-α blocker therapy are deter-
minants for continued treatment of PsA, in order to avoid risks
of reactivation of tubercular disease. We have proposed that
PsA patients with LTBI under anti-TNF-α therapy should
undergo clinical and laboratory standard evaluation every
3months and a chest radiograph every 6 months. Even patients
negative for TST and IGRA should undergo clinical and lab-
oratory standard evaluation every 3 months, but they could
perform chest radiograph and IGRA every 12 months. At any
time, in case of fever and symptoms and/or signs of suspected
TB reactivation, they should stop biologic therapy and perform
a chest X-ray and other appropriate diagnostic and therapeutic
measures [15]. In conclusion, our experience suggests that
anti-TNF-α treatment is effective and safe in PsA patients with
concomitant LTBI. Therefore, neither LTBI nor chemoprophy-
laxis seems to influence the course of anti-TNF-α therapy.
Moreover, an accurate diagnosis and management of LTBI
could reduce the risk of reactivation of tuberculosis. Further
studies are needed to clarify the controversial question of the
monitoring of LTBI patients on biologic therapy who show
TST/IGRA positive conversion. At present, our approach is to
treat and monitor them as patients with LTBI at enrollment.
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